Current and Emerging Biomarkers and Surrogate Endpoints in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).

Alamgir M, Sohal A, Kowdley KV

DOI: 10.1007/s40265-026-02369-z
Published: 2026 Oct
Container: Drugs
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s40265-026-02369-z,
  title = {Current and Emerging Biomarkers and Surrogate Endpoints in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).},
  author = {Alamgir M and Sohal A and Kowdley KV},
  year = {2026},
  journal = {Drugs},
  doi = {10.1007/s40265-026-02369-z},
  url = {https://doi.org/10.1007/s40265-026-02369-z}
}

RIS

TY  - JOUR
TI  - Current and Emerging Biomarkers and Surrogate Endpoints in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
AU  - Alamgir M
AU  - Sohal A
AU  - Kowdley KV
PY  - 2026
JO  - Drugs
DO  - 10.1007/s40265-026-02369-z
UR  - https://doi.org/10.1007/s40265-026-02369-z
ER  -

APA

M, A., A, S., & KV, K. (2026). Current and Emerging Biomarkers and Surrogate Endpoints in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).. Drugs. https://doi.org/10.1007/s40265-026-02369-z

Source records

pubmed · retrieved 2026-09-26T01:01:58.434Z
europe-pmc · retrieved 2026-09-26T01:01:58.438Z